IGF2 and colorectal carcinoma: Inhibiting IR-A expression causing a concomitant promotion of IGF-1R activation through IGF-I and IGF-II, decreasing the formation of IGF-1R: IR-A hybrid receptors, and enhancing IGF-1R homodimer formation in CRC cells.